Objective To evaluate the value of serum carcinoma embryonic antigen(CEA)levels in curative effect of cryoablation in metastatic lung adenocarcinoma patients. The prognosis of serum CEA levels in these patients was also assessed.
Methods It was collected that the clinical data of 56 patients with metastatic lung adenocarcinoma who underwent comprehensive (47 patients with lung tumor cryoablation) or palliative (9 patients without lung tumor cryoablation) therapy. Pre- and post-cryoablation serum CEA levels were evaluated, and overall survival was followed up in these patients.
Results Serum CEA levels were different in 5% of patients with metastatic lung adenocarcinoma compared with the palliative treatment team; the serum CEA levels decreased significantly in the comprehensive treatment team (P=0.0033). In the comprehensive treatment team, the median survival time was 26 months for patients with normal CEA expression level preoperatively. For patients with increased CEA expression level, the median survival time was 12 months. Patients with normal pretreatment serum CEA levels can live longer (P=0.0023).
Conclusion Serum CEA can be used as an indicator to evaluate the therapeutic effects in cryoablation therapy of metastatic lung adenocarcinoma. Serum CEA level can also be used as a predictor of survival for these patients.
[Key words] Cryosurgery; Carcinoma embryonic antigen; Metastatic lung adenocarcinoma
Metastatic lung adenocarcinoma.pdf